Preview

The Ectd Advantage - White Paper

Powerful Essays
Open Document
Open Document
1506 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
The Ectd Advantage - White Paper
August 20, 2009
The eCTD Advantage
By Michelle Perez

Life science companies in today’s shrinking economy are looking for ways to maintain growth in the face of imminent patent expiration, growing generic competition, and escalating drug development cost. One way an increasing number of sponsors are cutting expenses and time to market is by transitioning to the electronic Common Technical Document (eCTD) format right from the Investigational New Drug (IND) application. The eCTD has a number of features that can speed up submission publishing and review times, including cross-application linking capabilities that allow sponsors to submit a document just once and refer to it as many times as necessary in subsequent submissions and applications.

Focusing on the IND as a product application starting point (and the typical beginning of the clinical trial period), this article will address eCTD structure and functionality and outline the possibilities and pitfalls of building a submission strategy that takes advantage of the cross-application linking feature to achieve the following: • Cut publishing and review times in the NDA; • Improve submission and lifecycle management functions across all product applications.

The eCTD: ICH Format Designed for Efficiency
The Common Technical Document (CTD) was developed by the International Conference on Harmonization (ICH) and is fast becoming the preferred or required submission format by regulators in the world’s major marketplaces and beyond. Since July 2003, the CTD has been mandated for marketing and post-marketing applications in Europe, Japan, and Canada. The Food and Drug Administration (FDA) has required eCTD submissions since 2008, and the European Medicines Agency (EMEA) wants all Centralised Procedure applications in the eCTD format by the start of 2010. Although the industry has been bracing for change for some time now, many drug makers are making the transition to eCTD just ahead of regulatory deadlines.



References: • The ISI 2008 Emerging Biopharmaceutical Pulse Survey; Image Solutions, Inc. • Preparing Compliant eCTDs; Regulatory Affairs Professionals Society (RAPS) • Fastest Drug Developers Consistently Outperform Their Peers, Generating Substantially Higher Revenue and Cost Savings ; Tufts Center for the Study of Drug Development; September/October 2006 Tufts CSDD Impact Report • DIA Webinar: The New Look at eCTD Lifecycle Management: How Mapping from NDA to IND can Streamline Submission Lifecycle Chores; June 4, 2009; Michelle Perez, ISI, Connie Robinson-Kuiperi, FDA-CDER

You May Also Find These Documents Helpful

  • Powerful Essays

    [ 4 ]. Morgan, Steve, and Clare Mochrie. "Pharmaceutical Innovation: Can health and economic goals be met?" Centre for Health Services and Policy Research (July 2008): 1-9…

    • 1012 Words
    • 5 Pages
    Powerful Essays
  • Satisfactory Essays

    TCO 2 deals with new experimental drugs and the steps required to bring new drugs to market. The first application paper deals with this as well. Describe the steps that are required to bring a new pharmaceutical to market. Address topics like human testing, the role of the FDA in approving new drugs, and the cost incurred by drug companies when developing new drugs.…

    • 660 Words
    • 3 Pages
    Satisfactory Essays
  • Powerful Essays

    Management. Appendix A: Issues in Electronic Health Records Management.” Journal of AHIMA 75, no. 9 (Oct. 2004): Web extra.…

    • 3649 Words
    • 15 Pages
    Powerful Essays
  • Better Essays

    Holdren, J. P., Lander, E., Varmus, H., and et al. (2010 December). Report to the President Realizing the Full Potential of Health Information Technology To Improve Healthcare for Americans: The Path Forward. Executive Office of the President, Council of Advisors on Science and Technology. Retrieved from:…

    • 1118 Words
    • 5 Pages
    Better Essays
  • Better Essays

    Case Study 1

    • 2103 Words
    • 9 Pages

    Larsen, Marc G. . "Technology In Healthcare Leveraging New Innovations." Healthcare Executive 23.5 (2008): 9-14. Print.…

    • 2103 Words
    • 9 Pages
    Better Essays
  • Powerful Essays

    The initiative is defined by the FDA as a step towards alleviating the under treatment of common conditions or diseases by using innovative technologies or other conditions of safe use to expand which drug products can be considered nonprescription. Under this initiative, FDA plans to expand the nonprescription drug market by coming up with a different regulatory approach and approve a prescription drug to be used as OTC if certain conditions of safe use are…

    • 1315 Words
    • 6 Pages
    Powerful Essays
  • Better Essays

    Pharmanet-i3, a subsidiary of inVentive Health, is a world leading clinical research organization committed to the advancement of health around the world. The mission of Pharmanet-i3 is to be a strategic partner to companies that develop therapeutic drugs, and aim to bring drugs to the public that treat disease and improve the quality of life. The company will operate within the industry’s highest quality standards with uncompromising integrity, ethics, and respect for employees, study participants, the environment, and the communities in which the employees live and work. Shareholders can expect superior returns through the implementation of a successful growth strategy (Pharmanet-I3, n.d.).…

    • 1342 Words
    • 6 Pages
    Better Essays
  • Powerful Essays

    References: 1. Cramer, Joseph. 2010. “How to Choose the ‘Right’ Electronic Medical Record System”. Modern Medicine. Retrieved Mar 6, 2011 from www.modernmedicine.com…

    • 1341 Words
    • 6 Pages
    Powerful Essays
  • Powerful Essays

    The research and development of new medicines is a long and costly process. It usually takes up to 12 years and costs more than $200 million.…

    • 4301 Words
    • 18 Pages
    Powerful Essays
  • Better Essays

    During this step, the organization, environment, and individuals involved in the project were assessed in order to either adopt or reject the innovation. This overall assessment, concluded that the project was adopted by the organization and the key stakeholders. Additionally, the project setting is also supportive in the adoption of the project. The third component in the process is decision. The provider and nurses are the ones that will ultimately decide to adopt the screening tools. It is during this stage that the provider or nurses can either adopt or reject the…

    • 3978 Words
    • 16 Pages
    Better Essays
  • Better Essays

    Emr Paper

    • 6950 Words
    • 28 Pages

    References: Azron Incorporated 1998. Charting the Course™ for Electronic Medical Records. Carlsbad, California, August 18. INTERNET. (1998, November 27).…

    • 6950 Words
    • 28 Pages
    Better Essays
  • Satisfactory Essays

    Matrix Beavis, J Morgan, &Pickeri ng, J Byrd, F. H., Burns, B., & Grosskla gs, B. L Khomeir an, R. T., Yekta, Z. P., Kiger, A. M., & Ahmadi, Lorber, M., & Skela Savič, B Evidence-Based Practice Matrix of Ten Pieces of Primary Outcome Resource/ Year of Population/ Research Type Variables Database Publication Sample Size Measured Percentage of dialysis nurses and employees PubMed 2012 Quantitative 100 who finished competenci es by testing technology Google Scholar Google Scholar PubMed Central 2012 2010 2011 Quantitative Qualitative Quantitative Research on One Topic Related to Nursing Pertinent Data from Results…

    • 747 Words
    • 14 Pages
    Satisfactory Essays
  • Best Essays

    Uopx Career Action Plan

    • 1589 Words
    • 7 Pages

    * My decision to work with Electronic Medical Records (EMR) stems from my interest in health care with a lack of interest in clinical patient care. The role of EMRs is growing by leaps and bounds (Polack, 2012). In the 1990s…

    • 1589 Words
    • 7 Pages
    Best Essays
  • Good Essays

    Yamada reorganization of drug discovery at GlaxoSmithKline (GSK) following a merger to combat bureaucracy in decision making, approval, and authorization. This reorganization was necessary for the continued success of the company. Often the process for drug discovery and market is a slow and tedious process which can cost a company a lot in resources and financially. The smaller biotech companies are able to move quicker and push new drugs to market faster. The shift, Yamada thinks, will help produce an entrepreneurial environment akin to a smaller, biotechnology outfit. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery (CEDD). Each CEDD focused on a small set of therapeutic areas and possessed decision rights over the progression of pharmaceutical compounds through the early stages of development. These groups managed the pipeline from Lead Optimization through Proof of Concept. Each CEDD had full control over its own budget which could be spent internally or externally to deliver their best possible pipeline. The goals in each of these moves was to drive accountability deeper into the organization, reduce central oversight as much as necessary and foster a “biotech-like” atmosphere in a very large bio/pharmaceutical company.…

    • 756 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    Acceptance Limits for Api

    • 2272 Words
    • 10 Pages

    This article reviews the history of Cleaning Validation Acceptance Limits for Active Pharmaceutical Ingredients (APIs) and identifies where the currently used industry limits came from.…

    • 2272 Words
    • 10 Pages
    Powerful Essays